The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).
 
Tony Mok
Employment - The Chinese University of Hong Kong
Honoraria - Amgen; AstraZeneca; AVEO; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Eisai; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; AVEO; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Eisai; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
 
David Spigel
Consulting or Advisory Role - Novartis
Speakers' Bureau - Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Enriqueta Felip
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Roche Pharma AG
 
Filippo deMarinis
No Relationships to Disclose
 
Myung-Ju Ahn
No Relationships to Disclose
 
Harry J.M. Groen
Consulting or Advisory Role - Lilly (Inst); Roche Pharma AG (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Roche Pharma AG (Inst)
 
Heather A. Wakelee
Honoraria - Biocon; Peregrine Pharmaceuticals
Consulting or Advisory Role - Peregrine Pharmaceuticals
Research Funding - Agennix (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - Biocon; Peregrine Pharmaceuticals
 
Toyoaki Hida
Honoraria - Chugai Pharma; Pfizer
Research Funding - Chugai Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Lucio Crino
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer
 
Makoto Nishio
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Chugai Pharma; Elekta; Lilly; Nicholas Piramal; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Giorgio V. Scagliotti
Honoraria - AstraZeneca; Clovis Oncology; Lilly; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Lilly; Roche Pharma AG
Speakers' Bureau - Lilly
 
Fabrice Branle
Employment - Novartis
 
Chetachi Emeremni
Employment - Novartis
 
Massimiliano Quadrigli
Employment - Novartis; Novartis (I)
 
Jie Zhang
Employment - Daiichi Sankyo; Daiichi Sankyo (I); Novartis; Novartis (I)
Stock and Other Ownership Interests - Daiichi Sankyo; Daiichi Sankyo (I); Novartis; Novartis (I)
 
Alice Tsang Shaw
Honoraria - Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Genentech; Ignyta; Novartis; Pfizer; Roche Pharma AG
Research Funding - ARIAD (Inst); Genentech (Inst); Novartis (Inst); Pfizer (Inst)